Apyx Medical Corporation
APYX
$0.9934
-$0.1666-14.36%
| Weiss Ratings | APYX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | APYX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | APYX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.05 | |||
| Price History | APYX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -21.78% | |||
| 30-Day Total Return | -34.21% | |||
| 60-Day Total Return | -41.91% | |||
| 90-Day Total Return | -30.04% | |||
| Year to Date Total Return | -36.93% | |||
| 1-Year Total Return | -35.07% | |||
| 2-Year Total Return | -67.95% | |||
| 3-Year Total Return | -84.83% | |||
| 5-Year Total Return | -73.37% | |||
| 52-Week High % Change | -41.71% | |||
| 52-Week Low % Change | 24.72% | |||
| Price | APYX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.99 | |||
| 52-Week Low Price | $0.93 | |||
| 52-Week Low Price (Date) | Mar 13, 2025 | |||
| 52-Week High Price (Date) | May 10, 2024 | |||
| Valuation | APYX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 43.84M | |||
| Enterprise Value | 50.99M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.66 | |||
| Earnings Per Share Growth | 23.04% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.92 | |||
| Price/Book (Q) | 3.09 | |||
| Enterprise Value/Revenue (TTM) | 1.06 | |||
| Price | $0.99 | |||
| Enterprise Value/EBITDA (TTM) | -2.79 | |||
| Enterprise Value/EBIT | -2.71 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | APYX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 38.22M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | APYX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 727 384 2323 | |||
| Address | 5115 Ulmerton Road Clearwater, FL 33760-4004 | |||
| Website | apyxmedical.com | |||
| Country | United States | |||
| Year Founded | 1982 | |||
| Profitability | APYX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -39.17% | |||
| Profit Margin | -48.77% | |||
| Management Effectiveness | APYX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -16.35% | |||
| Return on Equity | -- | |||
| Income Statement | APYX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 48.10M | |||
| Total Revenue (TTM) | 48.10M | |||
| Revenue Per Share | $1.26 | |||
| Gross Profit (TTM) | 29.36M | |||
| EBITDA (TTM) | -18.25M | |||
| EBIT (TTM) | -18.85M | |||
| Net Income (TTM) | -23.46M | |||
| Net Income Avl. to Common (TTM) | -23.46M | |||
| Total Revenue Growth (Q YOY) | -3.00% | |||
| Earnings Growth (Q YOY) | 51.59% | |||
| EPS Diluted (TTM) | -0.66 | |||
| EPS Diluted Growth (Q YOY) | 56.33% | |||
| Balance Sheet | APYX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 31.74M | |||
| Cash Per Share (Q) | $0.83 | |||
| Total Current Assets (Q) | 56.44M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 14.34M | |||
| Current Ratio (Q) | 5.264 | |||
| Book Value Per Share (Q) | $0.38 | |||
| Total Assets (Q) | 64.84M | |||
| Total Current Liabilities (Q) | 10.72M | |||
| Total Debt (Q) | 38.76M | |||
| Total Liabilities (Q) | 50.51M | |||
| Total Common Equity (Q) | 14.21M | |||
| Cash Flow | APYX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -722.00K | |||
| Cash from Financing (TTM) | 6.75M | |||
| Net Change in Cash (TTM) | -11.91M | |||
| Levered Free Cash Flow (TTM) | -11.58M | |||
| Cash from Operations (TTM) | -18.05M | |||
